CRM — Salesforce, Inc.

Sentiment flipped hard bullish after the Q2 FY27 report on 2026-08-26: revenue of $11.35B (+11% YoY), non-GAAP EPS of $5.90, cRPO +14% to $33.5B, and Agentforce/Data 360 ARR above $1.5B (+240% YoY), with FY27 revenue guidance raised $200M to $46.1-46.4B. That combination converted the prior 'AI will eat seat-based SaaS' fear into an 'AI is accretive' narrative, driving a 23-34% four-week rally that carried the stock to $247.72 by 2026-09-13, near its 52-week high of $269.11 (the low was $146.32). Sell-side is aligned: 72 Buy/Strong Buy vs 21 Hold and 2 Sell, average target $269.64. The genuine caveat the tape is glossing over: $2.53 of the $5.90 non-GAAP EPS came from a $2.6B one-time net gain on strategic investments (Anthropic), so the operating beat was far narrower than the headline, and the trailing one-week return of -4.44% shows the first profit-taking.

Revenue growth inflected, then wobbled: YoY was +8.6% in the Oct-2025 quarter, +12.1% in Jan-2026, +13.3% in Apr-2026, then +10.8% in the Jul-2026 quarter ($11.345B vs $10.236B). So the reacceleration off the FY24/FY25 trough (~7.6% YoY in the Apr-2025 quarter) is real, but the most recent print decelerated ~250bp sequentially - either a one-quarter blip (fewer selling days, FX) or the first sign the AI uplift is levelling. Operating margin tells a similar story of structural improvement that has now stalled: 17.2% in Oct-2023 climbed steadily to 20.0% by Oct-2024, then 18.2% (Jan-2025), 19.8% (Apr-2025), a peak of 22.8% (Jul-2025), 21.3%, 21.9%, 21.8%, and back down to 20.5% in the Jul-2026 quarter - a 230bp YoY decline, with R&D rising to 14.9% of revenue from 14.5%. Net income grew from $1.22B (Oct-2023) to $2.11B (Apr-2026) on a normalised basis, but the Jul-2026 quarter's $3.53B includes a $2.6B one-time investment gain (~$3.16 per diluted share), so underlying profitability did not jump the way the headline suggests. Cash generation is the cleanest line: FY25 FCF $12.43B, FY26 FCF $14.40B, TTM FCF $15.15B, with the usual seasonality (Apr-2026 quarter $6.56B vs Jul-2026 quarter $1.10B). Bottom line: a quality franchise that has expanded margins by ~300bp over three years and re-accelerated growth, but is now showing plateau rather than acceleration in the newest quarter.

Mixed, and less cheap than the 'Cheap vs. its own history' tag implies. As of 2026-09-13 the stock is at $247.72 on TTM GAAP EPS of $11.783 = 22.5x; strip the $2.6B one-time gain out of TTM net income ($9.66B reported, ~$7.06B ex-gain) and the trailing multiple is closer to 28-29x. FMP's next-FY EPS estimate of $16.644 implies a 14.9x forward P/E, but that estimate requires ~41% EPS growth off a TTM base that already contains a one-off gain - I treat it as aggressive and lean on the more defensible ~$13.50 of ex-gain non-GAAP earnings power, which puts the stock near 18x. On cash the picture is better: 7.5% TTM FCF yield and ~15.4x EV/FCF ($233.9B EV against $15.15B TTM FCF), or ~15x EV/EBITDA using the screener's 14.99x. P/S of 4.62x sits 34% below the 5-year average of 7.02x, but that average was set when revenue grew 20%+, not 11%, so a chunk of the de-rating is structural rather than mispricing. PEG of 0.388 looks absurdly cheap but is an artefact of a distorted growth input. Verdict: fair, with an attractive cash-flow yield, but not the deep-value setup the raw P/S comparison suggests.

The market is already paying for the AI reacceleration story rather than waiting for it. At $247.72 the stock has re-rated on a quarter whose beat leaned on a $2.6B non-operating gain and whose revenue growth actually decelerated to 10.8% from 13.3%. That makes this a 'prove-it' setup: the next two data points - cRPO and revenue growth at Q3 FY27 in late Nov/early Dec 2026 - have to confirm the Agentforce thesis, and the multiple leaves little room for a soft guide. Two offsets are worth watching: the EPS tailwind from the ASR (diluted shares fell from ~957M in Oct-2025 to ~822M in Jul-2026, a 14% reduction) is mechanical and will keep per-share numbers growing faster than revenue, and Agentforce ARR compounding from $1.5B at +240% would justify a higher multiple than 15x EV/FCF. So the skew is: good news on cRPO = sharp upside to the $325 analyst high; a deceleration print = fast mean-reversion toward the 50-day (~$199) that the stock gapped away from.

As of 2026-09-13, RSI(14) stood at 64.89 - elevated but not yet overbought - with price 7.41% above the 20-day SMA (~$231), 24.73% above the 50-day (~$199) and 23.18% above the 200-day (~$201). That is a textbook parabolic, earnings-gap trend: +28.14% in one month, +49.33% in three months, +28.47% in six months, with the first cooling in the last week (-4.44%). Price at $247.72 versus the 52-week range of $146.32-$269.11 is ~8% off the high and 69% off the low. Entry-timing implication: buying a stock 25% extended above its 50-day days after a gap is poor risk/reward even if the business is fine; the natural accumulation zones are the 20-day retest (~$230) and the pre-earnings gap fill around $199-205. A loss of the $199 area would break the trend that the AI narrative built.

• Enterprise software budgets are under AI-ROI scrutiny: CIOs are funding Agentforce/Data 360 partly by consolidating seats, so Salesforce's upside and its disruption risk come from the same budget line.
• A moderating interest-rate backdrop helps long-duration software multiples and lowers the refi cost on $39.3B of long-term debt raised largely to fund buybacks (interest expense now a meaningful ~$1.5-2B annual drag).
• Sector divergence: the broader software basket (IGV, Adobe and peers) has been flat-to-down over the past month while CRM's +28% move is idiosyncratic - it can keep running, but it also means no sector tailwind if the AI story cools.
• Currency: the FY27 guidance raise was $300M in constant currency but only $200M as reported, implying roughly $100M of FX headwind - a reminder that reported growth carries translation noise.
• AI/data regulation (EU AI Act, data residency, emerging rules on autonomous agents) plus antitrust attention on large enterprise software bundling can slow Agentforce deployments or add compliance cost.

• Dreamforce Investor Day on 2026-09-16 - the nearest real catalyst; management must validate Agentforce ARR durability and a credible FY28 framework.
• Q3 FY27 earnings (late Nov/early Dec 2026) - the first hard test of whether cRPO growth holds above 14% and whether revenue growth re-accelerates past the 10.8% printed in the Jul-2026 quarter.
• Agentforce/Data 360 ARR compounding from $1.5B (+240% YoY); any new disclosure of a multi-billion-dollar AI ARR target would re-rate the AI contribution.
• Continued execution of the $25B accelerated share repurchase - diluted shares already fell from ~957M to ~822M, mechanically lifting EPS growth above revenue growth.
• Dividend policy (1.28% yield) and any new capital-return authorization; also the potential for the strategic investment portfolio (Anthropic stake) to be monetised or marked up further.
• Post-Dreamforce analyst revisions: consensus target $269.64 with a $325 high implies meaningful dispersion, so estimate resets are a swing factor.

• AI disruption of the seat-based model: the bull case requires Agentforce to more than offset pricing/seat pressure, and Microsoft (Dynamics 365), Oracle and AI-native vendors are pushing the opposite way.
• Earnings quality: Q2 FY27's headline beat leaned on a $2.6B one-time investment gain (~$3.16/diluted share), and the single-quarter accruals ratio flipped positive (+2.06% of assets) precisely because reported net income outran operating cash flow - a pattern the deterministic score penalises, and one that flatters the optics.
• Growth durability: YoY revenue growth decelerated to 10.8% in the Jul-2026 quarter from 13.3% in Apr-2026; if cRPO slips below ~14%, the reacceleration thesis and the multiple both compress.
• Balance sheet transformation: long-term debt jumped from $10.4B (Jan-2026) to $39.3B (Jul-2026) and equity fell from $59.1B to $38.4B to fund the buyback; current ratio of 0.839 and debt/equity of 1.088 leave less cushion if free cash flow dips, and depreciation/interest now chew into cash returns.
• Margin plateau: operating margin fell to 20.5% in the Jul-2026 quarter from 22.8% a year earlier as R&D intensity rose - the steady-margin-expansion story has stalled.
• Valuation and positioning after a 49% three-month run: RSI 64.89 and price 24.7% above the 50-day leave very little tolerance for a soft guide, especially with the stock less than 8% below its 52-week high.
• Structurally low ROIC (~8.8%) and ROE (~12.6%) despite 77% gross margins - the goodwill-heavy M&A model still has to earn its cost of capital.

Good business, reasonable price, unattractive entry timing. On the numbers I can defend, CRM is worth roughly $285 a share versus $247.72 on 2026-09-13 - so there is real upside, but it arrives with a caveat: the stock has already banked a 49% three-month re-rating on a quarter whose beat came substantially from a $2.6B one-time investment gain while revenue growth actually slowed to 10.8%. I would own this on a pullback toward the 20-day (~$231) or the pre-earnings gap ($200-205), or after the Sept-16 Dreamforce Investor Day and Q3 FY27 print confirm that Agentforce ARR and cRPO are compounding; chasing a stock 25% above its 50-day days before a binary narrative event is a worse trade than the fundamentals justify. This is analysis, not personalised financial advice.

A five-year DCF on SBC-adjusted free cash flow: I started from TTM FCF of $15.15B, applied a 15% haircut for stock-based compensation (base ~$12.9B), grew it 11% for years 1-3 (matching FY27 guidance and recent trajectory) and 8% for years 4-5, used a 3.5% terminal growth rate and a 10% discount rate (beta 1.20 plus an AI-disruption premium), producing a present value of $269B. Subtracting net debt of $31.0B ($39.29B debt less $8.31B cash) and dividing by ~830M diluted shares gives roughly $286, which I round to $285 - the number is corroborated by ~17x forward EPS of $16.644 and a ~21x multiple on ex-gain non-GAAP earnings power, and I deliberately excluded the strategic investment portfolio (Anthropic stake) as an unquantified offsetting conservatism.